Equity Overview
Price & Market Data
Price: $1.67
Daily Change: -$0.03 / 1.80%
Range: $1.63 - $1.85
Market Cap: $20,369,992
Volume: 154,639
Performance Metrics
1 Week: -12.11%
1 Month: 1.21%
3 Months: -16.50%
6 Months: -93.16%
1 Year: -91.63%
YTD: -51.45%
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.